Nearly a decade since the introduction of first-generation Bruton’s tyrosine kinase (BTK) inhibitors in the treatment of chronic lymphocytic leukaemia (CLL), their use has expanded with the second-generation agents zanubrutinib and acalabrutinib. These agents show high efficacy particularly in patients with TP53 mutations or del(17p).

GMA301 is a novel antagonistic antibody in clinical development. GMA301 targets human endothelin receptor A (ETA), a proven therapeutic target for pulmonary arterial hypertension (PAH).

Salt sensitive hypertension is a major risk factor for stroke, heart failure, and end-stage renal disease [1]. The development of salt sensitive hypertension is involved in genetic and environmental factors. Excessive dietary salt intake is known as a main risk factor and one of the most important environmental determinants, exacerbates the salt sensitive hypertension by a renal redox metabolism [2,3].

Hypertension remains as one of the most important public health challenges worldwide because of the associated morbidity, mortality, and the cost to the society. Despite the availability of safe and effective antihypertensive medications and the existence of clear treatment guidelines, hypertension is still inadequately controlled in a large proportion of patients worldwide. Unawareness of lifestyle modifications, and failure to apply these were one of the identified patient-related barriers to blood pressure control.